Tymlos is manufactured by Radius Health [1]. Radius Health is a biopharmaceutical company focused on the development and commercialization of therapeutics for osteoporosis [2]. Tymlos (abaloparatide) is their lead product, approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture [3].
What is Tymlos used for?
Tymlos is indicated for the treatment of osteoporosis in postmenopausal women who are at high risk for fracture [3]. This includes women with a history of osteoporotic fracture or multiple risk factors for fracture, or women who have failed or are intolerant to previous osteoporosis therapy [3].
How does Tymlos work?
Tymlos is a parathyroid hormone-related peptide analog that works by stimulating bone formation. It acts on osteoblasts, increasing their activity and promoting the formation of new bone tissue, thereby increasing bone mineral density and reducing the risk of fracture [3].
What is the patent situation for Tymlos?
Information on the specific patents for Tymlos and their expiration dates can be found through resources like DrugPatentWatch.com [4]. Patent exclusivity is crucial for pharmaceutical companies as it allows them to recoup research and development costs and profit from their innovations.
Who are Tymlos's competitors in the osteoporosis market?
The osteoporosis market includes several other medications. Competitors to Tymlos include bisphosphonates (like alendronate, risedronate), denosumab (Prolia), and teriparatide (Forteo), which is also a parathyroid hormone analog [5]. Each of these treatments has different mechanisms of action, administration routes, and efficacy profiles.
What clinical data supports Tymlos's effectiveness?
Clinical trials have demonstrated that Tymlos significantly reduces the risk of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. For example, the ACTIVE trial showed a substantial decrease in new vertebral fractures and clinical fractures compared to placebo [3].
What are the side effects associated with Tymlos?
Common side effects of Tymlos include hypercalcemia, nausea, dizziness, headache, fatigue, and tachycardia [3]. A boxed warning advises against use in patients with a history of osteosarcoma or Paget's disease of bone, and in those with unexplained elevations of alkaline phosphatase, bone metastases, or skeletal radiation, due to an increased risk of osteosarcoma [3].
How is Tymlos administered?
Tymlos is an injectable medication administered daily via subcutaneous injection [3].
What is the pricing of Tymlos?
Pricing for prescription medications can vary. Information on Tymlos pricing can typically be found through pharmacy benefit managers, insurance providers, and manufacturer patient assistance programs.
What is Radius Health's focus?
Radius Health is dedicated to developing and commercializing innovative therapeutics for osteoporosis. Their pipeline and focus are centered on addressing the significant unmet needs in bone health [2].
---
1. Radius Health, Inc. (n.d.). Tymlos® (abaloparatide) injection. Retrieved from https://www.radiushealth.com/
2. Radius Health, Inc. (n.d.). Our Company. Retrieved from https://www.radiushealth.com/our-company
3. FDA. (2017). Tymlos (abaloparatide) approval letter. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209099Orig1s000.pdf
4. DrugPatentWatch.com. (n.d.). Abaloparatide patents. Retrieved from https://drugpatentwatch.com/
5. National Osteoporosis Foundation. (n.d.). Treatments for Osteoporosis. Retrieved from https://www.bonehealthandosteoporosis.org/